专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明专利

CA2891976A1 IMIDAZOPYRIDINE COMPOUNDS 未知
公开(公告)号：CA2891976A1
公开(公告)日：2014-06-05
申请号：CA2891976
申请日：2013-11-28
申请人： ASTELLAS PHARMA INC
发明人： KUROSAKI TOSHIO , WATANABE TSUBASA , OHNE KAZUHIKO , ISHIOKA HIROKI , NOZAWA EISUKE , HANAZAWA TAKESHI , HACHIYA SHUNICHIRO , SHIBATA HIROSHI , KOGA YUJI , MIZOGUCHI RYO
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/506 , A61P7/02 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P43/00
摘要： [Problem] To provide a medicinal composition which functions to activate soluble guanylate cyclase (sGC) and which is for the treatment or prevention of various cardiovascular diseases that is based on an improvement in cGMP signals. [Solution] An imidazo[1,2-a]pyridine compound represented by formula (I), which has a carbamoyl group at the 3-position of the imidazo[1,2-a]pyridine framework and has a specific ring group bonded to the 8-position through a methyleneoxy group, or a salt of the compound. The pyridine compound or salt functions to activate sGC and is useful as the active ingredient of a medicinal composition for the treatment or prevention of various cardiovascular diseases in which sGC participates, in particular, peripheral arterial diseases, intermittent claudication, critical limb ischemia, hypertension, and pulmonary hypertension. (In formula (I), A1 is cyclohexyl, phenyl substituted by 1-3 fluorine atoms, or 3-fluoropyridin-2-yl and R is a group represented by any of the formulae (i) to (vii).)

22. 发明专利

ZA201002605B OXADIAZOLIDINEDIONE COMPOUND 未知
公开(公告)号：ZA201002605B
公开(公告)日：2011-06-29
申请号：ZA201002605
申请日：2010-04-14
申请人： ASTELLAS PHARMA INC
发明人： KURAMOTO KAZUYUKI , SOGA TAKATOSHI , TSUCHIYA KAZUYUKI , YOSHIDA SHIGERU , NEGORO KENJI , OHNUKI KEI , KUROSAKI TOSHIO , IWASAKI FUMIYOSHI
摘要： A pharmaceutical agent having GPR40 receptor agonistic action, particularly a compound which is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus. The present inventors have examined a compound having GPR40 receptor agonistic action, confirmed that an oxadiazolidinedione compound which has a substituent such as a benzyl group, etc. linked with a substituent such as a phenyl group, etc. through a linker at the 2-position of an oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof has an excellent GPR40 agonistic activity, and thus completed the invention. The oxadiazolidinedione compound has excellent insulin secretagogue action and anti-hyperglycemic action, and therefore can be used as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.

23. 发明专利

AU2008314963A1 Oxadiazolidinedione compound 未知
公开(公告)号：AU2008314963A1
公开(公告)日：2009-04-30
申请号：AU2008314963
申请日：2008-10-22
申请人： ASTELLAS PHARMA INC
发明人： NEGORO KENJI , IWASAKI FUMIYOSHI , SOGA TAKATOSHI , TSUCHIYA KAZUYUKI , KUROSAKI TOSHIO , OHNUKI KEI , KURAMOTO KAZUYUKI , YOSHIDA SHIGERU
IPC分类号： C07D271/06 , A61K31/4245 , A61K31/454 , A61P3/04 , A61P3/10 , A61P5/50 , A61P43/00 , C07D413/12
摘要： A pharmaceutical agent having GPR40 receptor agonistic action, particularly a compound which is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus. The present inventors have examined a compound having GPR40 receptor agonistic action, confirmed that an oxadiazolidinedione compound which has a substituent such as a benzyl group, etc. linked with a substituent such as a phenyl group, etc. through a linker at the 2-position of an oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof has an excellent GPR40 agonistic activity, and thus completed the invention. The oxadiazolidinedione compound has excellent insulin secretagogue action and anti-hyperglycemic action, and therefore can be used as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.

24. 发明专利

AR064049A1 DERIVADOS DE ACIDOS CARBOXILICOS UNIDOS A HETEROCICLOS, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, Y USOS COMO PROMOTORES DE LA SECRECION DE INSULINA EN EL TRATAMIENTO DE LA DIABETES MELLITUS. 未知
公开(公告)号：AR064049A1
公开(公告)日：2009-03-11
申请号：ARP070105327
申请日：2007-11-30
申请人： ASTELLAS PHARMA INC
发明人： ASAI NORIO , YONETOKU YASUHIRO , OHNUKI KEI , YOSHIDA SHIGERU , NEGORO KENJI , IWASAKI FUMIYOSHI , SOGA TAKATOSHI , TSUCHIYA KAZUYUKI , KUROSAKI TOSHIO
IPC分类号： C07D217/04 , C07D217/06 , C07D217/16 , C07D217/24 , C07D209/08 , C07D265/36 , C07D401/06 , C07D401/10 , C07D405/06 , C07D417/10 , C07D487/04 , A61K31/472 , A61K31/404 , A61K31/538 , A61P3/10
摘要： Reivindicacion 1: Un derivado de ácido carboxílico representado por la siguiente formula (1), o una sal farmacéuticamente aceptable del mismo (los símbolos de la formula representan los siguientes significados; R1: -H, alquilo inferior, halogeno- alquilo inferior, cicloalquilo, arilo, grupo heterocíclico, alquileno inferior-RA, C(O)RB, -CO2RB o -S(O)pRB, con la condicion de que el alquileno inferior, arilo y grupo heterocíclico de R1 puedan estar respectivamente sustituidos, RA: cicloalquilo, arilo, grupo heterocíclico, -S(O)pR0, -S(O)p-arilo, -S(O)p-grupo heterocíclico, -C(O)R0, -C(O)-arilo, -C(O)-grupo heterocíclico, -CO2R0, -OR0, -O-arilo, -O-grupo heterocíclico, -N(R0)2, -N(R0)-arilo, -N(R0)-grupo heterocíclico, - CO(R0)(arilo)2, -C(O)N(R0)-cicloalquilo o -C(O)N(R0)-arilo, con la condicion de que el arilo y el grupo heterocíclico de RA puedan estar respectivamente sustituidos, RB: alquilo inferior, halogeno-alquilo inferior, cicloalquilo, arilo, grupo heterocíclico, alquileno inferior-cicloalquilo, alquileno inferior-arilo, alquileno inferior-grupo heterocíclico, alquileno inferior-OR0, alquileno inferior-O-arilo o alquileno inferior-S(O)2NH2, con la condicion de que el arilo y el grupo heterocíclico de RB puedan estar respectivamente sustituidos, R0: -H o alquilo inferior, n y p: son iguales o diferentes entre sí y cada uno de ellos representa 0, 1 o 2, J: -C(R6)(R7)-, -O- o -S-, R2, R3, R6 y R7: son iguales o diferentes entre sí y cada uno de ellos representa -H, halogeno, alquilo inferior, -OR0 o arilo, con la condicion de que R2 y R3, R3 y R6, y R6 y R7 pueden formar juntos un alquileno inferior, R4: -H o alquilo inferior, X: enlace sencillo, -CH2-, -(CH2)2-, -O-, -S-, - S(O)- o -S(O)2-, Y: -CH2- o -C(O)-, Z: C(-*), C(R8), N o N(O), con la condicion de que el * de Z signifiqué union a L, X1 y X2: son iguales o diferentes entre sí y cada uno de ellos representa C(R9), N o N(O), X3 y X4: son iguales o diferentes entre sí y cada uno de ellos representa C(R10), N o N(O), R5: alquilo inferior, halogeno, halogeno-alquilo inferior, -OR0 o -O-halogeno-alquilo inferior, R8, R9 y R10: son iguales o diferentes entre sí y cada uno de ellos representa -H, alquilo inferior, halogeno, halogeno-alquilo inferior, -OR0 o -O- halogeno-alquilo inferior, con la condicion de que R6 y R10 pueden formar juntos un alquileno inferior, -O-alquileno inferior o alquileno inferior-O-, L: -O-alquileno inferior, alquileno inferior-O-, - N(R11)-alquileno inferior, alquileno inferior-N(R11), -O-alquileno inferior-O-, -N(R11)-alquileno inferior-N(R11)-, -O-alquileno inferior-N(R11)- o -N(R11)-alquileno inferior-O-, y R11: -H, alquilo inferior o -C(O)R0).

25. 发明专利

AT419250T 未知
公开(公告)号：AT419250T
公开(公告)日：2009-01-15
申请号：AT04793389
申请日：2004-10-29
申请人： ASTELLAS PHARMA INC
发明人： SHIMA ICHIRO , KURODA AKIO , OHKAWA TAKEHIKO , KUROSAKI TOSHIO , SAWADA YUKI , WADA AIKO
IPC分类号： C07D471/08 , A61K31/4025 , A61P3/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D451/04 , C07D453/02 , C07D487/08
摘要： A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X 1 and X 2 each is independently lower alkylene; X 3 is -CH 2 , -CHF or -CF 2 ; R 1 is substituent, R 2 and R 3 each is independently H or lower alkyl; n is 0, 1, 2, 3 or 4.] having the activity inhibiting DPP-IV activity. They are therefore useful in the treatment of conditions mediated by DPP-IV, such as NIDDM.

26. 发明专利

CA2650124A1 OXADIAZOLIDINEDIONE COMPOUND 未知
公开(公告)号：CA2650124A1
公开(公告)日：2007-11-01
申请号：CA2650124
申请日：2007-04-23
申请人： ASTELLAS PHARMA INC
发明人： SOGA TAKATOSHI , YOSHIDA SHIGERU , NEGORO KENJI , ASAI NORIO , IWASAKI FUMIYOSHI , YONETOKU YASUHIRO , OHNUKI KEI , KUROSAKI TOSHIO
IPC分类号： C07D271/06 , A61K31/4245 , A61K31/4439 , A61P3/08 , A61P3/10 , A61P43/00 , C07D413/12
摘要： [Problem] A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided. [Means for resolution] It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.

27. 发明专利

AU2004285809A1 2-cyanopyrrolidinecarboxamides as dipeptidyl peptidase-IV inhibitors 未知
公开(公告)号：AU2004285809A1
公开(公告)日：2005-05-12
申请号：AU2004285809
申请日：2004-10-29
申请人： ASTELLAS PHARMA INC
发明人： WADA AIKO , KUROSAKI TOSHIO , KURODA AKIO , SHIMA ICHIRO , SAWADA YUKI , OHKAWA TAKEHIKO
IPC分类号： A61K31/4025 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D471/08 , C07D487/08

28. 发明专利

PL2927231T3 ZWIĄZKI IMIDAZOPIRYDYNY 未知
公开(公告)号：PL2927231T3
公开(公告)日：2018-01-31
申请号：PL13858992
申请日：2013-11-28
申请人： ASTELLAS PHARMA INC
发明人： KUROSAKI TOSHIO , WATANABE TSUBASA , OHNE KAZUHIKO , ISHIOKA HIROKI , NOZAWA EISUKE , HANAZAWA TAKESHI , HACHIYA SHUNICHIRO , SHIBATA HIROSHI , KOGA YUJI , MIZOGUCHI RYO
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/506 , A61P7/02 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P43/00

29. 发明专利

MX2015006856A COMPUESTOS IMIDAZOPIRIDINA. 未知
公开(公告)号：MX2015006856A
公开(公告)日：2016-02-17
申请号：MX2015006856
申请日：2013-11-28
申请人： ASTELLAS PHARMA INC
发明人： KUROSAKI TOSHIO , NOZAWA EISUKE , KOGA YUJI , HANAZAWA TAKESHI , OHNE KAZUHIKO , WATANABE TSUBASA , SHIBATA HIROSHI , HACHIYA SHUNICHIRO , ISHIOKA HIROKI , MIZOGUCHI RYO
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/506 , A61P7/02 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P43/00
摘要： Se proporciona una composición farmacéutica para tratar o prevenir enfermedades cardiovasculares, que tienen actividades de sGC sobre la base de la mejora de las señales de cGMP. [Medio para la Solución] Se ha descubierto que compuestos de imidazo[1,2-a]piridina que tienen un grupo carbamoílo en la posición 3 y un grupo cíclico particular en la posición 8 por medio de un grupo metilenoxi, o una sal de este, tienen activación de sGC, y son útiles como ingredientes activos de composiciones farmacéuticas para tratar o prevenir diversas enfermedades cardiovasculares relacionadas con sGC, en particular, enfermedades de las arterias periféricas, claudicación intermitente, isquemia crítica de los miembros inferiores, hipertensión e hipertensión pulmonar, por lo cual se completa la presente invención.

30. 发明专利

AU2013353117A1 Imidazopyridine compound 未知
公开(公告)号：AU2013353117A1
公开(公告)日：2015-06-04
申请号：AU2013353117
申请日：2013-11-28
申请人： ASTELLAS PHARMA INC
发明人： KUROSAKI TOSHIO , WATANABE TSUBASA , OHNE KAZUHIKO , ISHIOKA HIROKI , NOZAWA EISUKE , HANAZAWA TAKESHI , HACHIYA SHUNICHIRO , SHIBATA HIROSHI , KOGA YUJI , MIZOGUCHI RYO
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/506 , A61P7/02 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P43/00
摘要： [Problem] To provide a medicinal composition which functions to activate soluble guanylate cyclase (sGC) and which is for the treatment or prevention of various cardiovascular diseases that is based on an improvement in cGMP signals. [Solution] An imidazo[1,2-a]pyridine compound represented by formula (I), which has a carbamoyl group at the 3-position of the imidazo[1,2-a]pyridine framework and has a specific ring group bonded to the 8-position through a methyleneoxy group, or a salt of the compound. The pyridine compound or salt functions to activate sGC and is useful as the active ingredient of a medicinal composition for the treatment or prevention of various cardiovascular diseases in which sGC participates, in particular, peripheral arterial diseases, intermittent claudication, critical limb ischemia, hypertension, and pulmonary hypertension. (In formula (I),

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式